DOCSLIB.ORG

W14. Movement Disorders for the Internist Dr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
W14. Movement Disorders for the Internist Dr Canadian Society of Internal Medicine Annual Meeting 2018 Banff, AB W14. Movement Disorders for the Internist Dr. Davide Martino, PhD MD Movement Disorders Program, DCNS, University of Calgary CSIM Annual Meeting 2018 The following presentation represents the views of the speaker at the time of the presentation. This information is meant for educational purposes, and should not replace other sources of information or your medical judgment. Conflict Disclosures “I have no conflicts to declare” LEARNING OBJECTIVES 1. Identify the type of tremor in patients with various presentations. 2. Determine which investigations are required in the evaluation of patients with new onset ataxic gait. 3. Manage restless legs syndrome and know which medications should not be used. LEARNING OBJECTIVE 1 IDENTIFY THE TYPE OF TREMOR IN PATIENTS WITH VARIOUS PRESENTATIONS Assign to this video one of the three possible syndromic diagnoses of tremor: A. Essential tremor B. Parkinsonian tremor C. Cerebellar tremor Diagnosis is clinical • Topography: Tremors can occur in any joint or muscle that is free to oscillate. Symmetry on the two sides can be important. • Frequency: For exact frequency measurement a signal analysis of accelerometric or EMG recordings is necessary. However, with some experience the three main frequency ranges can be separated on inspection: high (>7 Hz), medium (4-7 Hz) and low (<4 Hz). • Additional symptoms: e.g. parkinsonian syndrome, cerebellar ataxia or dystonia …and activation • Resting tremor occurs when the muscles of the affected body part are not voluntarily activated. Rest tremor must cease or be suppressed when a voluntary movement is initiated or performed. • Action tremor is any tremor that is produced by voluntary contraction of muscles and covers: • Postural tremor while voluntarily maintaining a position; • Kinetic tremor during voluntary movement. • Simple kinetic tremor is seen during purposeless voluntary movements. • Goal-directed tremor (most commonly labeled as intention tremor) occurs when a target is reached. • Rarer forms of action tremor occur only during certain positions or tasks, e.g. • task or position specific tremor • isometric tremor Assign to this video one of the three possible syndromic diagnoses of tremor: A. Essential tremor B. Parkinsonian tremor C. Cerebellar tremor Assign to this video one of the three possible syndromic diagnoses of tremor: A. Essential tremor B. Parkinsonian tremor C. Cerebellar tremor What is the most likely cause of this tremor? A. Idiopathic dystonia B. Exposure to neuroleptics (first generation antipsychotics) C. Dystonia D. Functional movement disorder E. Lithium exposure What is the most likely cause of this tremor? A. Parkinson’s disease B. Hyperthyroidism C. Dystonia D. Functional movement disorder E. Cerebellar lesion or degeneration LEARNING OBJECTIVE 2 DETERMINE WHICH INVESTIGATIONS ARE REQUIRED IN THE EVALUATION OF PATIENTS WITH NEW ONSET ATAXIC GAIT ? ? Metronidazole-induced acute ataxia [Hari et al. 2013] Age at onset With vestibular Viral infections: VZV (children)- symptoms/signs? EBV (adults) (nystagmus, vertigo, MS others) Persistent Cognitive/speech changes – tremor – Look for oculomotor myoclonus – seizures – SREAT sleep probl - psychosis Lithium abnormalities Phenytoin Acute- Paraneoplastic 5-fluorouracil Cognitive changes – nystagmus/abducens Wernicke Capecitabine CEREBELLAR Subacute palsy/papilloedema Cytosine arabinoside Onset Stroke Metronidazole Drugs/Toxins Amiodarone Drug history (CT)/MRI Hg-Pb-Mn Thyroid antibodies Toluene-benzene derivatives (anti-TPO + anti-Tg) Genetic episodic ataxias Alcohol-malnutrition Episodic If appropriate MS Paraneoplastic panel (anti- Stroke Hu, anti-Yo, anti-Ri, anti-CMV) CSF Episodic ataxias (aut dom) Attacks precipitated by stress or emotions EA1 (KCNA1) EA2 (CACNA1A) Delayed rectifier P/Q-type calcium channel alpha 1A subunit potassium channel, Kv1.1 Onset: late childhood Onset: infancy to early adulthood to adolescence Attacks: secs-mins Attacks: hours to days, with vertigo, nausea, ± headache Interictal myokimia or Interictal downbeat nystagmus, ataxia and neuromyotonia with rarely dystonia stiffness and weakness during Responds to acetazolamide or 4- attacks aminopyridine Responds to Allelic to SCA6, IGE, FHM type 1, congenital ataxia and acetazolamide hemiplegic migraine with cerebral edema Cognitive – depression - neuropathy – spastic Subacute Associated with para/tetraparesis combined Vitamin deficiency (B12, E, degeneration proprioceptive sensory folic acid) loss de-afferentation Neurosarcoidosis ataxia Vertebrobasilar insufficiency Acute- CDDP, cisplatin, Persistent Syphilis carboplatin, Subacute oxaliplatin Onset Doxorubicin Drugs/Toxins Bortezomib Sensory • Drug history Suramin sodium polyneuropathies • Vitamin B12 (MMA-Hcy) Thallium and E Penicillin • MRI spine • CXR/CT chest + serum markers of sarcoidosis (SAA, sIL-2R, ACE, KL-6) • Syphilis serology • NCS/CSF, anti-GQ1b Age at onset Cognitive/speech changes – tremor – myoclonus – seizures – SREAT sleep probl - psychosis Sporadic Paraneoplastic MRI Rapid Thyroid progression antibodies CSF/EEG Cognitive – psychosis and agitation - CJD depression Inherited GSS (PRNP gene: P102L most frequently) What is the most likely diet that has improved this patient’s ataxia? A. Low-protein diet B. Ketogenic diet C. Feingold diet D. Atkins diet E. Gluten-free diet [Hernàndez-Lahoz et al. 2014] What is the most likely diet that has improved this patient’s ataxia? A. Low-protein diet B. Ketogenic diet C. Feingold diet D. Atkins diet E. Gluten-free diet [Hernàndez-Lahoz et al. 2014] 66-yr old woman 4-year hx gait and hearing problems Forgetfulness – mood No hx of trauma or intradural surgery Babinski on the right Serum iron mildly decreased Serum ferritin mildly increased [Bae et al. J Mov Disord 2014] What is the most likely cause for this patient’s ataxia? A. Folic acid deficiency B. Neuroferritinopathy C. Superficial siderosis of the CNS D. Spontaneous intracranial hypotension E. Vitamin E deficiency 66-yr old woman 4-year hx gait and hearing problems Forgetfulness – mood No hx of trauma or intradural surgery Babinski on the right Serum iron mildly decreased Serum ferritin mildly increased [Bae et al. J Mov Disord 2014] What is the most likely cause for this patient’s ataxia? A. Folic acid deficiency B. Neuroferritinopathy C. Superficial siderosis of the CNS D. Spontaneous intracranial hypotension E. Vitamin E deficiency SLOW PROGRESSION ATAXIAS Sporadic Alcohol-related* chronic thiamine deficiency; 11-27% of chronic alcohol users // gait and LL>UL and speech // vermal atrophy Gluten ataxia* anti-TG6 IgA (73%) // most have cerebellar atrophy // responds to gluten-free diet // PNpathy in 40% Metabolic subacute combined degeneration* // vit.E, vit.B1 // hypothyroidism and hypoparathyroidism Toxic lithium, phenytoin, 5-FU, capecitabine, citarabine, metronidazole and other azoles, amiodarone, heavy metals and solvents (Hg, Pb, Mn, toluene/benzene derivatives) Infections neurosyphilis*, Lyme*, Whipple’s Superficial siderosis +hearing loss, pyramidal, cognitive, seizures, visual loss, hyposmia MSA-C and heredodegenerative ataxias LEARNING OBJECTIVE 3 MANAGE RESTLESS LEGS SYNDROME AND KNOW WHICH MEDICATIONS SHOULD NOT BE USED [from sleepdisorders.sleepfoundation.org CASE #1 National Sleep Foundation] 34-yr old nurse referred for early insomnia (on bad days latency of up to 2-3 hrs), non-refreshing sleep (frequent awakenings, 3-5 times per night, with achy legs; partner prefers to sleep in different bed), and malaise throughout the day Onset in late adolescence, but as a child she suffered from «growing pains» in her legs and feeling that her legs were only loosely attached to her body and at times hard to control Aches and irritating discomfort in her legs during the evening, initially attributed to stress and shiftwork – urgency to move her legs to alleviate the discomfort, especially when lying or sitting down (typically not occurring around a daytime nap) Relaxation training, sleep health habits, prescription hypnotics (temazepam 30mg hs) unsuccessful PSG observation of PLMS, with short arousals in 70% of them 5 cups of strong coffee throughout the day Serum ferritin = 24 ng/mL How do we approach this patient with RLS? Key questions 1. Have we ruled out the main causes of secondary RLS? What are these? o Medical conditions: iron deficiency ( Ferrous sulfate + vit.C), end-stage renal disease/on hemodialysis (vit.C + E suppl – ropinirole, L-dopa, exercise), obesity, COPD, DM, IBS o Neurological diseases: small fibre neuropathies, PD o Drugs: DR blockers, NSRIs, AEDs (e.g. zonisamide) o Pregnancy 2. Is RLS sufficiently severe to warrant specific treatment? o Strong evidence (AAN Level A) pramipexole [0.125, 0.25-0.5mg], rotigotine patch [1, 1-3mg], gabapentin enacarbil [600, 600mg] o Moderate evidence ropinirole [0.25, 0.25-4mg], pregabalin*, IV ferric carboxymaltase* [500mg given twice 5 days apart] o Weak evidence L-dopa* How do we approach this patient with RLS? Key questions 3. Should we target sleep disruption? o PLMS [PLMI index on PSG] causing frequent awakenings: ropinirole, pramipexole, rotigotine, pregabalin o Improving TST, sleep efficiency, sleep latency, wake after sleep onset: ropinirole, gabapentin enacarbil, pregabalin o Subjective sleep measures: gabapentin enacarbil, ropinirole, pregabalin>pramipexole, rotigotine, L-dopa 4. Risk of augmentation? o Pregabalin / Gabapentin enacarbil o Pramipexole / Ropinirole / Rotigotine o L-dopa How
Load more

Recommended publications
  • Eslicarbazepine Acetate Longer Procedure No
    European Medicines Agency London, 19 February 2009 Doc. Ref.: EMEA/135697/2009 CHMP ASSESSMENT REPORT FOR authorised Exalief International Nonproprietary Name: eslicarbazepine acetate longer Procedure No. EMEA/H/C/000987 no Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. product Medicinal 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE........................................... 3 1.1. Submission of the dossier ...................................................................................................... 3 1.2. Steps taken for the assessment of the product..................................................................... 3 2. SCIENTIFIC DISCUSSION................................................................................................. 4 2.1. Introduction............................................................................................................................ 4 2.2. Quality aspects ....................................................................................................................... 5 2.3. Non-clinical aspects................................................................................................................ 8 2.4. Clinical aspects....................................................................................................................
    [Show full text]
  • Chapter 25 Mechanisms of Action of Antiepileptic Drugs
    Chapter 25 Mechanisms of action of antiepileptic drugs GRAEME J. SILLS Department of Molecular and Clinical Pharmacology, University of Liverpool _________________________________________________________________________ Introduction The serendipitous discovery of the anticonvulsant properties of phenobarbital in 1912 marked the foundation of the modern pharmacotherapy of epilepsy. The subsequent 70 years saw the introduction of phenytoin, ethosuximide, carbamazepine, sodium valproate and a range of benzodiazepines. Collectively, these compounds have come to be regarded as the ‘established’ antiepileptic drugs (AEDs). A concerted period of development of drugs for epilepsy throughout the 1980s and 1990s has resulted (to date) in 16 new agents being licensed as add-on treatment for difficult-to-control adult and/or paediatric epilepsy, with some becoming available as monotherapy for newly diagnosed patients. Together, these have become known as the ‘modern’ AEDs. Throughout this period of unprecedented drug development, there have also been considerable advances in our understanding of how antiepileptic agents exert their effects at the cellular level. AEDs are neither preventive nor curative and are employed solely as a means of controlling symptoms (i.e. suppression of seizures). Recurrent seizure activity is the manifestation of an intermittent and excessive hyperexcitability of the nervous system and, while the pharmacological minutiae of currently marketed AEDs remain to be completely unravelled, these agents essentially redress the balance between neuronal excitation and inhibition. Three major classes of mechanism are recognised: modulation of voltage-gated ion channels; enhancement of gamma-aminobutyric acid (GABA)-mediated inhibitory neurotransmission; and attenuation of glutamate-mediated excitatory neurotransmission. The principal pharmacological targets of currently available AEDs are highlighted in Table 1 and discussed further below.
    [Show full text]
  • Acetazolamide
    Cambridge University Press 978-0-521-68716-4 - The Epilepsy Prescriber’s Guide to Antiepileptic Drugs Philip N. Patsalos and Blaise F. D. Bourgeois Excerpt More information the epilepsy prescriber’s guide to antiepileptic drugs ACETAZOLAMIDE A Therapeutics Chemical name and structure: Acetazolamide, N-(5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl)-aceta- mide, is a white to faintly yellowish white odorless crystalline powder with a molecular weight of 222.25. Although a sulfonamide compound, it is unlike sulfonamide anti- biotic compounds. It does not contain an arylamine group at the N4-position, which contributes to allergic reactions associated with sulfonamide antibiotics. The structure of acetazolamide bears some similarity to that of zonisamide. Its empirical formula is C4H6N4O3S2. NN O CH3 CNH SO2NH2 S THERAPEUTICS Brand names: r Acetadiazol; Acetak; Albox; Apo-Acetazolamide; Azol r Carbinib; Cetamid r Diamox; Diamox Sequals; Diamox Sustets; Diluran; Diural; Diuramid r Evamox r Fonurit r Glaupax r Huma-Zolamide r Ledamox; Lediamox r Medene r Optamide r Renamid r Stazol; Synomax r Uramox r Zolmide Generics available: r Yes Licensed indications for epilepsy: r Adjunctive treatment of generalized tonic–clonic and partial seizures (UK-SPC) r Adjunctive treatment of atypical absences, atonic, and tonic seizures (UK-SPC) r Intermittent therapy of catamenial seizures (UK-SPC) Licensed indications for non-epilepsy conditions: r Adjunctive treatment of glaucoma (UK-SPC; FDA-PI) r Prevention or amelioration of symptoms associated with acute mountain sickness (FDA-PI) 1 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-68716-4 - The Epilepsy Prescriber’s Guide to Antiepileptic Drugs Philip N.
    [Show full text]
  • Topiramate Is More Effective Than Acetazolamide at Lowering
    University of Birmingham Topiramate is more effective than acetazolamide at lowering intracranial pressure Scotton, William J; Botfield, Hannah F; Westgate, Connar Sj; Mitchell, James L; Yiangou, Andreas; Uldall, Maria S; Jensen, Rigmor H; Sinclair, Alex J DOI: 10.1177/0333102418776455 License: Creative Commons: Attribution (CC BY) Document Version Publisher's PDF, also known as Version of record Citation for published version (Harvard): Scotton, WJ, Botfield, HF, Westgate, CS, Mitchell, JL, Yiangou, A, Uldall, MS, Jensen, RH & Sinclair, AJ 2018, 'Topiramate is more effective than acetazolamide at lowering intracranial pressure', Cephalalgia. https://doi.org/10.1177/0333102418776455 Link to publication on Research at Birmingham portal Publisher Rights Statement: William J Scotton, Hannah F Botfield, Connar SJ Westgate, James L Mitchell, Andreas Yiangou, Maria S Uldall, Rigmor H Jensen, and Alex J Sinclair, Topiramate is more effective than acetazolamide at lowering intracranial pressure, Cephalalgia, First Published June 13, 2018; https://doi.org/10.1177/0333102418776455. Checked 02/07/2018. General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research. •User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.
    [Show full text]
  • Approach to Managing Patients with Sulfa Allergy Use of Antibiotic and Nonantibiotic Sulfonamides
    CME Approach to managing patients with sulfa allergy Use of antibiotic and nonantibiotic sulfonamides David Ponka, MD, CCFP(EM) ABSTRACT OBJECTIVE To present an approach to use of sulfonamide-based (sulfa) medications for patients with sulfa allergy and to explore whether sulfa medications are contraindicated for patients who require them but are allergic to them. SOURCES OF INFORMATION A search of current pharmacology textbooks and of MEDLINE from 1966 to the present using the MeSH key words “sulfonamide” and “drug sensitivity” revealed review articles, case reports, one observational study (level II evidence), and reports of consensus opinion (level III evidence). MAIN MESSAGE Cross-reactivity between sulfa antibiotics and nonantibiotics is rare, but on occasion it can affect the pharmacologic and clinical management of patients with sulfa allergy. CONCLUSION How a physician approaches using sulfa medications for patients with sulfa allergy depends on the certainty and severity of the initial allergy, on whether alternatives are available, and on whether the contemplated agent belongs to the same category of sulfa medications (ie, antibiotic or nonantibiotic) as the initial offending agent. RÉSUMÉ OBJECTIF Proposer une façon d’utiliser les médicaments à base de sulfamides (sulfas) chez les patients allergiques aux sulfas et vérifier si ces médicaments sont contre-indiqués pour ces patients. SOURCES DE L’INFORMATION Une consultation des récents ouvrages de pharmacologie et de MEDLINE entre 1966 et aujourd’hui à l’aide des mots clés MeSH «sulfonamide» et «drug sensitivity» a permis de repérer plusieurs articles de revue et études de cas, une étude d’observation et des rapports d’opinion consensuelles (preuves de niveau III).
    [Show full text]
  • Diamox/Aldactone to Increase the Urinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure
    Official Title: Diamox/Aldactone to Increase the URinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure NCT01973335 Date: August 27, 2015 DIURESIS-CHF – Study protocol version August 27, 2015 1 1. Background Aging of the population and prolongation of the lives of cardiac patients by modern therapeutic innovations have led to an increased incidence of congestive heart failure (CHF).1 During the last two decades, important progress has been made in the treatment of ambulatory CHF patients with reduced ejection fraction. Renin-angiotensin system blockers, β-blockers, mineralocorticoid receptor antagonists (MRA), ivabradine and cardiac resynchronization therapy have all demonstrated to reduce morbidity and/or mortality in ambulatory CHF patients.2-17 Despite these important advances, many patients are still hospitalized frequently with signs and symptoms of systemic congestion, which is associated with worse outcome.18 Treatment in these cases mainly focuses on symptomatic relief through administration of diuretics, although clear evidence on the optimal agent, dosing schedule, and administration route is lacking. Coexisting renal dysfunction often complicates decongestive treatment and worsening renal function (WRF), often defined as a 0.3 mg/dL rise in serum creatinine (Cr), is a common finding in this context.19 However, the prognostic impact of WRF, defined as Cr change is unsure as it might be associated with worse, neutral or even better outcome.20-22 In contrast, persistent congestion, as a reflection of the inability of the kidneys to preserve sodium homeostasis, has been more consistently associated with higher mortality and more frequent readmissions in CHF.23 This suggests that achieving a negative sodium balance might be an attractive treatment target in heart failure.
    [Show full text]
  • Which Diuretics Are Safe and Effective for Patients with a Sulfa Allergy?
    From the CLINIcAL InQUiRiES Family Physicians Inquiries Network Ron Healy, MD University of Washington, Which diuretics are safe Seattle; Alaska Family Medicine Residency, Anchorage and effective for patients Terry Ann Jankowski, MLS University of Washington, Seattle with a sulfa allergy? Evidence-based answer Diuretics that do not contain a sulfonamide subsequent allergic reactions to commonly group (eg, amiloride hydrochloride, used sulfonamide-containing diuretics eplerenone, ethacrynic acid, spironolactone, (eg, carbonic anhydrase inhibitors, loop and triamterene) are safe for patients with an diuretics, and thiazides) (strength of allergy to sulfa. The evidence is contradictory recommendation: C, based on case series ® as to whether a history Dowdenof allergy to Healthand poor Media quality case-control and cohort sulfonamide antibiotics increases the risk of studies). Copyright Clinical commentaryFor personal use only Are all sulfa drugs created equal? agents and off-patent, with no company Historical bromides commonly fall by the to take up their cause, no one has been FAST TRACK wayside as better evidence becomes willing to challenge outdated package Reasonable available. Who would have thought 15 insert warnings. years ago that we would be promoting As clinicians who regularly work evidence supports beta-blockers for patients with congestive without a net, we are accustomed to what many of us heart failure? prescribing medications in less than ideal are doing: Using Likewise, with closer inspection, we circumstances. Thankfully, reasonable cheap thiazides have learned that not all sulfa drugs are evidence is available to support what many created equal. The stereospecificity due of us are already doing—using cheap for patients to the absence of aromatic amines in thiazides for patients despite a history of with a history common diuretics means they are safe sulfa allergy.
    [Show full text]
  • Using Medications, Cosmetics, Or Eating Certain Foods Can Increase Sensitivity to Ultraviolet Radiation
    USING MEDICATIONS, COSMETICS, OR EATING CERTAIN FOODS CAN INCREASE SENSITIVITY TO ULTRAVIOLET RADIATION. INDIVIDUALS SHOULD CONSULT A PHYSICIAN BEFORE USING A SUNLAMP, IF THEY ARE TAKING MEDICATIONS. THE ITEMS LISTED ARE POTENTIAL PHOTOSENSITIZING AGENTS THAT MAY INCREASE SENSITIVITY TO ULTRAVIOLET LIGHT THAT MAY RESULT IN A PHOTOTOXIC OR PHOTOALLERGIC RESPONSES. PHOTOSENSITIZING MEDICATIONS Acetazolamide Amiloride+Hydrochlorothizide Amiodarone Amitriptyline Amoxapine Astemizole Atenolol+Chlorthalidone Auranofin Azatadine (Optimine) Azatidine+Pseudoephedrine Bendroflumethiazide Benzthiazide Bromodiphenhydramine Bromopheniramine Captopril Captopril+Hydrochlorothiazide Carbaamazepine Chlordiazepoxide+Amitriptyline Chlorothiazide Chlorpheniramine Chlorpheniramin+DPseudoephedrine Chlorpromazine Chlorpheniramine+Phenylopropanolamine Chlorpropamide Chlorprothixene Chlorthalidone Chlorthalidone+Reserpine Ciprofloxacin Clemastine Clofazime ClonidineChlorthalisone+Coal Tar Coal Tar Contraceptive (oral) Cyclobenzaprine Cyproheptadine Dacarcazine Danazol Demeclocycline Desipramine Dexchlorpheniramine Diclofenac Diflunisal Ditiazem Diphenhydramine Diphenylpyraline Doxepin Doxycycline Doxycycline Hyclate Enalapril Enalapril+Hydrochlorothiazide Erythromycin Ethylsuccinate+Sulfisoxazole Estrogens Estrogens Ethionamide Etretinate Floxuridine Flucytosine Fluorouracil Fluphenazine Flubiprofen Flutamide Gentamicin Glipizide Glyburide Gold Salts (compounds) Gold Sodium Thiomalate Griseofulvin Griseofulvin Ultramicrosize Griseofulvin+Hydrochlorothiazide Haloperidol
    [Show full text]
  • Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Acetazolamide Attenuates Lithium-Induced Nephrogenic Diabetes Insipidus de Groot, Theun ; Sinke, Anne P ; Kortenoeven, Marleen L A ; Alsady, Mohammad ; Baumgarten, Ruben ; Devuyst, Olivier ; Loffing, Johannes ; Wetzels, Jack F ; Deen, Peter MT Abstract: To reduce lithium-induced nephrogenic diabetes insipidus (lithium-NDI), patients with bipo- lar disorder are treated with thiazide and amiloride, which are thought to induce antidiuresis by a compensatory increase in prourine uptake in proximal tubules. However, thiazides induced antidiure- sis and alkalinized the urine in lithium-NDI mice lacking the sodium-chloride cotransporter, suggesting that inhibition of carbonic anhydrases (CAs) confers the beneficial thiazide effect. Therefore, we tested the effect of the CA-specific blocker acetazolamide in lithium-NDI. In collecting duct (mpkCCD) cells, acetazolamide reduced the cellular lithium content and attenuated lithium-induced downregulation of aquaporin-2 through a mechanism different from that of amiloride. Treatment of lithium-NDI mice with acetazolamide or thiazide/amiloride induced similar antidiuresis and increased urine osmolality and aquaporin-2 abundance. Thiazide/amiloride-treated mice showed hyponatremia, hyperkalemia, hypercal- cemia, metabolic acidosis, and increased serum lithium concentrations, adverse effects previously observed in patients but not in acetazolamide-treated mice in this study. Furthermore, acetazolamide treatment reduced inulin clearance and cortical expression of sodium/hydrogen exchanger 3 and attenuated the increased expression of urinary PGE2 observed in lithium-NDI mice. These results show that the antid- iuresis with acetazolamide was partially caused by a tubular-glomerular feedback response and reduced GFR.
    [Show full text]
  • Utah Medicaid Pharmacy & Therapeutics Committee
    Utah Medicaid Pharmacy & Therapeutics Committee Drug Class Review: Older Anticonvulsants Barbiturates, Anticonvulsants 28:12.04 Primidone (Mysoline®) Hydantoins 28:12.12 Ethotoin (Peganone®) Phenytoin (Dilantin-125®, Dilantin®, Dilantin® Infatabs®, Dilantin® Kapseals®, Phenytek® and generics) Succinimides 28:12:20 Ethosuximide (Zarontin®, Zarontin® Syrup) Methsuximide (Celontin® Kapseals®) Anticonvulsants, Miscellaneous 28:12.92 Carbamazepine (Carbatrol®, Epitrol®, Tegretol®, Tegretol® XR) Valproate Sodium, Valproic Acid, Divalproex Sodium (Depacon®, Depakene®, Depakote®, Depakote® ER, Depakote® Sprinkle, Stavzor®) Anticonvulsants, Miscellaneous 28:12.92 and 54:40.12 Carbonic Anhydrase Inhibitor Acetazolamide (Diamox®) Barbiturates 28:24.04 Pentobarbital (Nembutal® Sodium Solution) Phenobarbital (Luminal® Sodium and generic) Final Report October 2016 Prepared by: Vicki Frydrych BS, PharmD, Clinical Pharmacist University of Utah College of Pharmacy Copyright © 2016 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved 1 Table of Contents Executive Summary ...................................................................................................................................................... 3 Introduction ................................................................................................................................................................... 8 Table 1: Product Comparison ................................................................................................................................
    [Show full text]
  • Use of Acetazolamide in Lithium-Induced Nephrogenic Diabetes Insipidus: a Case Report
    ID: 17-0154 10.1530/EDM-17-0154 R A Macau, T N da Silva and Acetazolamide in lithium ID: 17-0154; February 2018 others nephrogenic DI DOI: 10.1530/EDM-17-0154 Use of acetazolamide in lithium-induced nephrogenic diabetes insipidus: a case report Ricardo A Macau1,*, Tiago Nunes da Silva2,*, Joana Rego Silva1, Ana Gonçalves Ferreira2 and Pedro Bravo1 Correspondence should be addressed 1Nephrology Department, Hospital Garcia de Orta and 2Endocrinology Department, Hospital Garcia de Orta, to R A Macau or T N da Silva Almada, Portugal Email ricardoandremacau@gmail. com or tiago_fcml@yahoo. *(R A Macau and T N da Silva contributed equally to this work) com Summary Lithium-induced nephrogenic diabetes insipidus (Li-NDI) is a rare and difficult-to-treat condition. A study in mice and two recent papers describe the use of acetazolamide in Li-NDI in 7 patients (a case report and a 6 patient series). We describe the case of a 63-year-old woman with bipolar disorder treated with lithium and no previous history of diabetes insipidus. She was hospitalized due to a bowel obstruction and developed severe dehydration after surgery when she was water deprived. After desmopressin administration and unsuccessful thiazide and amiloride treatment, acetazolamide was administrated to control polyuria and hydroelectrolytic disorders without significant side effects. To our knowledge, this is the third publication on acetazolamide use in Li-NDI patients. Learning points: • Treatment of lithium-induced nephrogenic diabetes insipidus might be challenging. • Vasopressin, amiloride and thiazide diuretics have been used in lithium-induced nephrogenic diabetes insipidus treatment. • Acetazolamide might be an option to treat lithium-induced nephrogenic diabetes insipidus patients who fail to respond to standard treatment.
    [Show full text]
  • Evaluation of Adverse Events in Self-Reported Sulfa-Allergic Patients Using Topical Carbonic Anhydrase Inhibitors
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS Volume 29, Number 5, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/jop.2012.0123 Evaluation of Adverse Events in Self-Reported Sulfa-Allergic Patients Using Topical Carbonic Anhydrase Inhibitors Guilherme B. Guedes,1 Abraar Karan,1 Hylton R. Mayer,2 and M. Bruce Shields1 Abstract Purpose: To investigate whether a self-reported history of allergy to sulfa-based drugs is a predictor for sub- sequent adverse reactions to topical carbonic anhydrase inhibitors (CAIs). Methods: A retrospective case-controlled cohort study via chart review was performed on 1,287 patients with a diagnosis of glaucoma. The outcome measure was the development of an adverse reaction (either ocular, systemic, or both) within at least 30 days after receipt of 1 of 4 classes of topical glaucoma medications: CAIs (dorzolamide and brinzolamide), prostaglandin analogues, beta-adrenergic blockers, and alpha2-adrenergic agonists. Results: Patients with a self-reported history of sulfa allergy had significantly more ocular adverse reactions after the initiation of any of the topical antiglaucoma medications when compared to those patients with no reported allergies. Patients with a self-reported sulfa allergy and patients who self-reported other, nonsulfa-related al- lergies had similar rates of adverse reactions to most of the topical medications. The patients reporting a sulfa allergy who used topical CAIs did not have more adverse reactions compared with patients who reported having other, nonsulfa-related allergies who used topical CAIs. Self-reported sulfa-allergic patients had similar rates of adverse reactions to topical CAIs compared with topical prostaglandin analogues. Conclusion: It may be safe to use a topical CAI in patients who report a history of a sulfa allergy.
    [Show full text]